A Review on the Relationship between SGLT2 Inhibitors and Cancer
Risk of increasing breast and bladder cancer remains a safety issue of SGLT2 (sodium glucose cotransporter type 2) inhibitors, a novel class of antidiabetic agent. We reviewed related papers published before January 29, 2014, through Pubmed search. Dapagliflozin and canagliflozin are the first two a...
Main Authors: | Hao-Wen Lin, Chin-Hsiao Tseng |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2014/719578 |
Similar Items
-
Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01) -
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01) -
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
by: Anastasios Tentolouris, et al.
Published: (2019-08-01) -
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
by: Bonora BM, et al.
Published: (2020-01-01) -
SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01)